Indivior PLC stock (GB00BYZ0C031): opioid-dependence specialist in the spotlight after latest earnings

Indivior PLC remains in focus after its recent quarterly update on its opioid-dependence portfolio and US litigation overhangs. Investors are watching how the specialty pharma group balances growth in treatments like Sublocade with ongoing legal and competition pressures.

Indivior PLC has stayed on the radar of healthcare investors following its latest quarterly earnings release and ongoing strategic updates around its opioid-use disorder franchise, led by long?acting injectable Sublocade. The specialty pharmaceutical group continues to navigate strong US demand, patent and litigation issues, and a shifting reimbursement landscape, according to company disclosures and recent coverage from financial media such as Reuters as of 03/14/2025 and investor materials published on the company website.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior
• Sector/industry: Specialty pharmaceuticals, addiction treatment
• Headquarters/country: Slough, United Kingdom
• Core markets: United States, selected international markets
• Key revenue drivers: Opioid-use disorder therapies, primarily buprenorphine-based products
• Home exchange/listing venue: London Stock Exchange (ticker: INDV)
• Trading currency: GBP

Indivior PLC: core business model

Indivior focuses on developing and commercializing medicines for substance-use disorders and serious mental illnesses, with a primary emphasis on opioid-use disorder. The company generates the majority of its revenue from buprenorphine?based therapies that aim to reduce cravings and withdrawal symptoms, thereby supporting long?term recovery for patients who are dependent on opioids, according to the company’s description of its business in its annual report published on March 14, 2025 for the 2024 financial year, as referenced by Indivior investor materials as of 03/14/2025.

A central pillar of Indivior’s strategy is the transition from older sublingual formulations to long?acting injectable treatments, most notably Sublocade in the US market. This shift is designed to improve adherence and clinical outcomes while also supporting a more durable revenue base with higher barriers to generic competition. The company operates a hybrid model, combining its own commercial infrastructure in key markets such as the United States with partnerships and distributors in selected regions to maximize reach while controlling operating costs.

Beyond opioid-use disorder, Indivior also has a smaller portfolio and pipeline targeting alcohol-use disorder and other related conditions. These programs are still less material than the core buprenorphine franchise but form part of the long?term plan to diversify the revenue mix over time. Research and development spending is focused on new formulations, longer?acting delivery technologies, and potential new indications that build on the company’s expertise in addiction science, according to management commentary in the 2024 full?year materials released on March 14, 2025 for the period ended December 31, 2024, cited by Reuters as of 03/14/2025.

Main revenue and product drivers for Indivior PLC

Sublocade, a once?monthly buprenorphine injection for moderate to severe opioid-use disorder, has become the primary growth engine for Indivior. In its full?year 2024 results published March 14, 2025 for the year ending December 31, 2024, the company reported that Sublocade net revenue increased strongly year over year, reflecting wider adoption in the United States, according to Indivior FY 2024 results press release as of 03/14/2025. The growth is being driven by treatment centers, specialty addiction clinics, and increasingly by broader healthcare providers as awareness of long?acting therapies expands.

Legacy sublingual tablet and film products, marketed under brands such as Suboxone in some markets, still contribute a meaningful share of Indivior’s sales, but these products face ongoing generic erosion and price pressure. Over the past several years, revenue from this part of the portfolio has declined as lower?priced generics gained share, particularly in the US. The company has stated that its strategy is to manage the decline while prioritizing resources toward Sublocade and newer products, according to commentary in the 2024 annual report published March 14, 2025 and summarized by Reuters as of 03/14/2025.

The US market is the dominant revenue contributor for Indivior because of the scale of the opioid-use disorder crisis and the established reimbursement mechanisms for addiction treatment. The company’s revenues are sensitive to coverage decisions by public payers and private insurers, as well as to policy initiatives that expand or restrict access to medication?assisted treatment. Outside the US, Indivior pursues growth in selected markets, but the international business remains smaller in absolute terms. For US?focused investors, this concentration means Indivior’s performance is closely tied to US healthcare policy and law?enforcement approaches to opioid misuse.

Conclusion

Indivior PLC offers exposure to the intersection of specialty pharmaceuticals and the ongoing US opioid-use disorder crisis, with Sublocade emerging as the key growth driver while older products continue to decline. The company’s outlook is influenced by factors such as US treatment guidelines, reimbursement decisions, competitive dynamics, and the resolution of outstanding legal matters. For US?oriented investors, Indivior represents a focused play on addiction treatment demand and policy trends, but also comes with typical sector risks including regulatory scrutiny, pricing pressure, and execution on its pipeline strategy. As with any healthcare stock, careful consideration of company disclosures, risk factors, and personal risk tolerance remains essential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.